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Diffuse large B-cell lymphoma is a clinically and molecularly heterogeneous disease. Gene
expression profiling studies have shown that the tumor microenvironment affects survival and
that the angiogenesis-related signature is prognostically unfavorable. The contribution of
histopathological microvessel density to survival in diffuse large B-cell lymphomas treated with
immunochemotherapy remains unknown. The purpose of this study is to assess the prognostic
impact of histopathological microvessel density in two independent series of patients with dif-
fuse large B-cell lymphoma treated with immunochemotherapy.  
Design and Methods
One hundred and forty-seven patients from the Leukemia Lymphoma Molecular Profiling
Project (training series) and 118 patients from the Catalan Lymphoma-Study group-GELCAB
(validation cohort) were included in the study. Microvessels were immunostained with CD31
and quantified with a computerized image analysis system. The stromal scores previously
defined in 110 Leukemia Lymphoma Molecular Profiling Project cases were used to analyze
correlations with microvessel density data.
Results
Microvessel density significantly correlated with the stromal score (r=0.3209; P<0.001).
Patients with high microvessel density showed significantly poorer overall survival than those
with low microvessel density both in the training series (4-year OS 54% vs. 78%; P=0.004) and
in the validation cohort (57% vs. 81%; P=0.006). In multivariate analysis, in both groups high
microvessel density was a statistically significant unfavorable prognostic factor independent of
international prognostic index [training series: international prognostic index (relative risk 2.7;
P=0.003); microvessel density (relative risk 1.96; P=0.002); validation cohort: international
prognostic index (relative risk 4.74; P<0.001); microvessel density (relative risk 2.4; P=0.016)].  
Conclusions
These findings highlight the impact of angiogenesis in the outcome of patients with diffuse
large B-cell lymphoma and the interest of evaluating antiangiogenic drugs in clinical trials. 
Key words: rituximab, aggressive non-Hodgkin’s lymphoma, kidney, central nervous system.
Citation: Cardesa-Salzmann TN, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F,
González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors
JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe Es, Staudt L, Jares P,
López-Guillermo A and Campo E. High microvessel density determines a poor outcome in patients
with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica
2011;96(7):996-1001.  doi:10.3324/haematol.2010.037408
©2011 Ferrata Storti Foundation. This is an open-access paper. 
High microvessel density determines a poor outcome in patients with diffuse
large B-cell lymphoma treated with rituximab plus chemotherapy 
Teresa M. Cardesa-Salzmann,1 Luis Colomo,1 Gonzalo Gutierrez,1 Wing C. Chan,2 Dennis Weisenburger,2 Fina Climent,3
Eva González-Barca,4 Santiago Mercadal,4 Leonor Arenillas,5 Sergio Serrano,5 Ray Tubbs,6 Jan Delabie,7 Randy D.
Gascoyne,8 Joseph M Connors,8 Jose L. Mate,9 Lisa Rimsza,10 Rita Braziel,11 Andreas Rosenwald,12 Georg Lenz,13
George Wright,14 Elaine S. Jaffe,14 Louis Staudt,14 Pedro Jares,1 Armando López-Guillermo,1,* and Elias Campo1,*
1Hospital Clinic, University of Barcelona, Barcelona, Spain; 2University of Nebraska Medical Centre, Omaha, NE, USA; 3Hospital
Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain; 4Institut Catalá d’Oncología, Hospital Duran i Reynals, L’Hospitalet de
Llobregat, Spain; 5Hospital del Mar, Barcelona, Spain; 6Cleveland Clinic, Cleveland, OH, USA; 7The Norwegian Radium Hospital,
Oslo, Norway; 8British Columbia Cancer Agency, Vancouver, BC, Canada; 9Hospital Germans Trias, Badalona, Spain; 10University 
of Arizona Cancer Center, Tucson, AZ, USA; 11Oregon Health Sciences University, Portland, OR, USA; 12University of Würzburg,
Würzburg, Germany; 13Molekulares Krebsforschungszentrum (MKFZ) Charité – Universitätsmedizin Berlin; and 14NCI, NIH,
Bethesda, MD, USA
*ALG and EC are co-senior authors
ABSTRACT
996 haematologica | 2011; 96(7)
Introduction
Diffuse large B-cell lymphomas (DLBCL) are a heteroge-
neous group of tumors with different biological and clini-
cal characteristics highlighted by the diverse clinical out-
come of the patients. The addition of rituximab (R) has
increased the survival of these patients by 10-15%,1 but
further risk stratification is necessary to improve the treat-
ment strategies and outcome. Gene expression profiling
(GEP) studies have shown that differences in the tumor
microenvironment of DLBCL affect survival after treat-
ment. A survival-predictor score, based on a multivariate
model derived from the germinal center B-cell, stromal-1
and stromal-2 gene expression signatures, has the capabil-
ity of predicting survival among patients with DLBCL
treated with R-CHOP (rituximab plus cyclophosphamide,
doxorubicin, vincristine and prednisone).2 While the ‘stro-
mal-1-signature’, related to extracellular matrix deposition
and histiocytic infiltration is prognostically favorable, the
angiogenesis-related signature (‘stromal-2 signature’) is
associated with an unfavorable outcome.2 GEP studies
provide very robust prognostic information but are not
routinely available for most patients. Several studies have
provided increasing evidence that angiogenesis plays a
role in the biology of lymphomas3-8 and particularly in
DLBCL.9-11 The increasing attention given to new thera-
peutic strategies targeting angiogenesis in malignant neo-
plasias emphasizes the interest in assessing vascular den-
sity in the tumors to determine its prognostic relevance
and biological impact. In the era of new anti-angiogenic
therapies, a reliable stratification of patients with DLBCL
according to the vascular density of their tumors may be
useful to determine whether these new therapies might
benefit all or only a subset of patients. 
The purpose of our study was to evaluate whether the
microvascular density in DLBCL quantified on tissues by
a computer based imaging system has an impact on the
outcome of these patients. This analysis was performed in
two independent cohorts of patients treated with ritux-
imab-based chemotherapeutic regimens.
Design and Methods 
Clinical characteristics 
A training group of 147 patients (79 males, 68 females; median
age 64 years) with de novo DLBCL diagnosed between 1997 and
2007 was selected from the Leukemia Lymphoma Molecular
Prophiling Project (LLMPP) consortium database based on the
availability of formalin-fixed tissue material. Cases with trans-
formed DLBCL, primary mediastinal large B-cell lymphoma
(PMBCL), intravascular and primary effusion lymphomas, as well
as immunodeficiency-associated tumors were excluded from the
study. All patients were treated with rituximab-containing
chemotherapy combinations (R-CT), in most cases, R-CHOP.
Details of patients’ main clinico-biological features, including ther-
apy, are shown in Table 1. Median follow up of surviving patients
was 3.7 years (range 0.13-11.3 years). Complete remission (CR)
rate was 72%, whereas 4-year progression free survival (PFS) and
overall survival (OS) were 56% and 66%, respectively. The defini-
tions of CR, PFS and OS were based on standard criteria.12
An independent series of 118 patients (66 males, 52 females;
median age 62 years) with de novo DLBCL diagnosed between
1999 and 2007 at the hospitals of the Catalan Lymphoma Study
consortium (GELCAB) was used to validate the results. Thirty
patients from the Hospital Clinic of Barcelona were initially
included in the LLMPP studies and were not, therefore, considered
in the GELCAB validation set. Median follow up of surviving
patients was 3.85 years (range 0.12-9.7 years). The histological cri-
teria to include the cases were the same as for the LLMPP patients.
All the patients received R-CT. Main clinico-biological features of
the patients included from the GELCAB series are listed in Table
1. Complete remission rate was 85.7% and 4-year PFS and OS
were 63% and 68%, respectively. The list of the participating
institutions from the LLMPP and the GELCAB consortiums are
detailed in the appendices. Patients gave their informed consent
according to the guidelines of the ethics committees involved.
Gene expression profiling (GEP) 
Gene-expression profiling data from the LLMPP series were
available in 110 cases. This information is accessible at
www.nci.nlm.nih.gov/geo/query/acc.cig?token=rhojvaiekdsihq&acc=GS
E10846, accession number GSE10846. Molecular subtyping of the
DLBCL, according to the GEP signatures, included 47 germinal
center B-cell (GCB) DLBCL, 53 activated B-cell (ABC) type
DLBCL, and 10 unclassifiable cases. The previously defined gene
expression stromal scores were used to analyze the correlations
between GEP results and the microvasculature study data. 
Immunohistochemistry and blood vessel density 
measurements 
Tissue microarrays (TMAs) were constructed from pre-treat-
ment biopsy specimens using duplicated cores of 1 mm per tumor
sample. All cases were reviewed by a panel of experts in
hematopathology. Samples were stained in an automated Bond®
immunostainer with an antibody against CD31 (DAKO; 1/40 dilu-
tion, incubation of primary antibody for 30 min, antigen retrieval
at pH 6 for 20 min). The microvessel density (MVD) was quanti-
fied using the digitalized images of the CD31-stained TMA cores
(Figure 1) acquired with an Olympus BX51 microscope at x4 mag-
nification and analyzed with an Olympus Cell B Basic Imaging
Software. Microvessel areas were defined as vascular areas delin-
eated by CD31+ staining. The MVD was calculated as the sum of
all microvessel areas (μm2) divided by the total area of the core
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Table 1. Main clinical features of LLMPP and GELCAB cohorts.
                                                     LLMPP                           GELCAB
                                                     N=147                            N=118
Sex (Male/Female)                             79/68                                      66/52
Median age (range)                 64 ( 22-91) years                 62 (19-87) years
Ann Arbor stage                         I-II= 47.4% (65)                  I-II=43.6% (51)
                                                      III-IV= 51.1% (70)              III-IV=56.4% (66)
Extranodal sites
0.1                                                  87.8% (93)                            90.4% (85)
≥2                                                  12.2% (13)                              9.6% (9)
IPI score
0-1: Low risk                                  42% (60)                             34.5% (39)
2-3: Low-intermediate risk
High-intermediate risk      48.3% (69)                            54.3% (50)
4-5: High risk                                 9.8% (14)                             21.2% (24)
Treatment 
R-CHOP                                            80.5% (128)                         91.6% (108)
R-CHOP-“like”*                              19.5% (19)                             8.4% (10)
*R-CHOP-like regimens - LLMPP series: R-CNOP (rituximab, cyclophosphamide, mitox-
antrone, vincristine, prednisone), 12 cases; R-ESHAP (rituximab, etoposide, methylpred-
nisolone, cytarabine, cis-platin), 3; R-CFM (rituximab, cyclophosphamide, fluorouracil,
methotrexate), 4. GELCAB series: R-high dose-CHOP/R-ESHAP,  9 cases; R-CNOP,  1.
analyzed (μm2). MVD values were grouped in quartiles when nec-
essary and considered high or low when above or below the 50th
percentile respectively. TMAs were independently scored by 2
observers and discrepancies were resolved over a double-headed
microscope. To determine whether the angiogenic values scored
using TMA cores were representative of the tumor sample, in 40
cases microvessels were evaluated in whole tissue sections (WTS)
and in TMA cores from the same tumor and compared by linear
regression analysis. Three areas of the size of a TMA core rich in
neoplastic cells were evaluated on each WTS for CD31+ MVD.
The mean value of the three MVD measures in each WTS was
compared to the MVD of the corresponding TMA core by linear
regression analysis.
Statistical analysis 
Categorical data were compared using Fisher’s exact test with
two-sided P values. For ordinal data, non-parametric tests were
used. Spearman’s correlation test was used to analyze the degree
of linear association between MVD and the stromal scores or GEP
data. The multivariate analysis of the variables predicting response
was performed using a logistic regression analysis. The actuarial
survival analysis was performed according to the Kaplan-Meier
method, and the curves were compared by log rank test. The mul-
tivariate analysis for survival was performed with Cox’s stepwise
proportional hazards model.
Results 
Results in the training series
Microvessel density (MVD) 
The microvascular areas of the DLBCL cores showed
great variability (Figure 1). The MVD values ranged
between 0.77¥10-3 and 92.7¥10-3 (mean 14¥10-3). To deter-
mine whether the results obtained in the TMAs were rep-
resentative of the whole tumor section (WTS), we studied
the MVD in TMA cores and in the corresponding WTS of
40 cases. This comparison showed an excellent correlation
between the MVD values in both types of samples
(r=0.90; P<0.001).
Microvessel density and gene expression profiling 
The stromal score had been previously defined as the
component of the multivariate survival model composed
by the difference between the stromal-2 and stromal-1 sig-
nature averages.2 In the LLMPP DLBCL cohort, there was
a significant correlation between MVD and stromal score
(r=0.3209; P<0.001) (Figure 2). The entire set of the genes
in the array platform was analyzed for statistical correla-
tion with MVD with none of the genes showing a
stronger correlation than that expected by chance. There
was no statistically significant correlation between CD31
mRNA expression levels and the immunohistochemical
CD31+ MVD. 
DLBCL of the GCB type showed MVD mean values
that were significantly lower than ABC type DLBCL
(11.8±12.2¥10-3 vs. 15.0±12.4¥10-3, respectively; P=0.05). 
The main clinical features of the LLMPP series according
to the MVD (low vs. high MVD) are listed in Table 2.
Patients with advanced Ann Arbor stages showed higher
MVD values than those with early stages (P=0.01). There
was no correlation with other initial clinical characteris-
tics. No significant differences were observed in terms of
CR rates according to MVD values. Sixty-four patients
eventually experienced failure to therapy or relapse with a
4-year PFS of 56% (95%CI: 47-65%). Patients with high
MVD in the biopsy had shorter PFS than those with low
MVD values (4-year PFS 48% vs. 65%, respectively;
P=0.048) (Figure 3A). MVD and IPI had independent prog-
nostic value for PFS (Table 3).
After a median follow up for surviving patients of four
years, 46 patients had died, with a 4-year OS of 66%
(95%CI: 58-74%). Patients with high MVD had a signifi-
cantly poorer OS than those with low MVD (4-year OS:
54% vs. 78%, respectively; P=0.004) (Figure 3B). Other
variables predicting poor OS were ABC-type DLBCL as
assessed by GEP (P=0.001), poor performance status
(P<0.001), and high serum LDH levels (P=0.001). As
expected, IPI scores also showed prognostic impact for
PFS (P<0.001) and OS (P<0.001). A multivariate analysis
was performed, including IPI (low vs. intermediate vs.
T.M. Cardesa-Salzmann et al.
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Figure 1. CD31 staining of DLBCL TMA
cores. (A1, A2) High microvessel density
and (B1, B2) low microvessel density. Image
acquisition at x40 (A1, B1) and x100 (A2,
B2) with an Olympus SC20 microscope. 
high-risk) and MVD (low vs. high). In the final model,
with 143 cases, both IPI (relative risk (RR) 2.7; P=0.003)
and MVD (RR 1.96; P=0.002) maintained independent
prognostic significance (Table 3). To analyze whether the
prognostic interest of MVD was independent from molec-
ular subtyping (GCB vs. ABC types), MVD (continuous
variable) and molecular type were included in the model
(n=100 cases), with both MVD (RR 1.057; P<0.001) and
molecular subtype (RR 2.21; P=0.024) maintaining their
prognostic value for OS. Finally, a multivariate analysis
was performed including MVD (low vs. high) along with
molecular type (GCB vs. ABC types) and IPI (low vs. inter-
mediate vs. high-risk). In the final model, molecular sub-
type (RR 2.65; P=0.004) and IPI (RR 1.6; P=0.025) were the
most important variables to predict OS. 
Results in the validation cohort
One hundred and eighteen DLBCL patients of the GEL-
CAB were used to validate the LLMPP results. In this
series, MVD values ranged between 0.37 and 181¥10-3
(mean 16¥10-3). There was no significant difference
between these values and those found in the training set.
In the validation set, no correlation was observed between
MVD and main clinical features at presentation. The 4-
Vascular density in diffuse large B-cell lymphoma 
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Table 2. Main clinical features and MVD.
LLMPP GELCAB
(training cohort) (validation set)
N=147 N=118
MVD low MVD high MVD low MVD high
Median age (years) 64 (23-91) 64 (30-88) 64 (19-87) 61 (22-83)
Gender (M/F) 37/36 42/32 35/25 31/27
Advanced stage 40 62 53 60
(III-IV) (%)
IPI (%)
Low risk 51 33 39 31
L/I or H/I risk 42 55 44 44
High risk 7 12 17 25
CR rate (%) 79 66 88 83
4-year PFS (%) 65 48 72 54
P=0.048 P=0.03
4-year OS (%) 78 54 81 57
P=0.004 P=0.006
Figure 2. Spearman’s correlation test. Linear regression analysis
between microvessel density (MVD) and stromal score. 
Figure 3. Kaplan-Meier survival analysis according to low and high microvessel density (MVD). (A) Progression-free survival (PFS) and (B)
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year PFS of the series was 62% (95%CI: 52-72%). Patients
with high MVD in the biopsy (Table 2) had shorter PFS
than those with low MVD values (4-year PFS 54 vs. 72%,
respectively; P=0.03) (Figure 3C). After a median follow
up for surviving patients of 3.85 years, 35 patients had
died, with a 4-year OS of 68% (95%CI: 61-71%). Patients
with high MVD showed significantly shorter OS in com-
parison to those with low MVD (4-year OS 57% vs. 81%,
respectively; P=0.006) (Figure 3D). A multivariate analysis
was performed for the training sample, including IPI (low
vs. intermediate vs. high risk) and MVD (low vs. high). In
the final model with 111 cases, both IPI (RR 4.74; P<0.001)
and MVD (RR 2.4; P=0.016) maintained independent
prognostic importance for OS (Table 3). Finally, the
merged analysis of both series, training and validation set,
including 265 patients, is shown in Figure 3E and F.
Patients with high MVD had shorter PFS than those with
low MVD values (4-year PFS 50% vs. 68%, respectively;
P=0.003) (Figure 3E). Patients with high MVD showed sig-
nificantly shorter OS in comparison to those with low
MVD (4-year OS 55% vs. 79%, respectively; P=0.0001)
(Figure 3F).
Discussion 
In this study, we have shown that differences in the
blood vessel density of DLBCLs have a consistent relation-
ship with the outcome of patients treated with R-CT.
Patients with a high MVD show a significantly poorer PFS
and OS than those with a low MVD. These results were
evident in two independent series of DLBCL patients
treated with R-CT and maintained their independent
prognostic value in a multivariate analysis. Thus, an
increased MVD was able to discriminate patients with
poor-risk DLBCL independently of the IPI risk groups. The
possibility of recognizing patients who have a significant-
ly worse prognosis due to a highly vascularized tumor can
be useful in the light of the many new antiangiogenic ther-
apies which are now available and which can be incorpo-
rated into clinical trials. 
Increased MVD has also been described as a negative
prognostic factor in solid tumors but has not been
explored in DLBCL treated with R-CT.13 The prognostic
value of the MVD in our study agrees with previously
published GEP data on DLBCL.2 The gene expression sig-
natures ‘stromal 1’ and ‘stromal 2’, related to extracellular
matrix and angiogenesis-related genes, respectively, were
synergistic in predicting survival. These two signatures
were combined into the stromal score and high values of
this score predicted an adverse clinical outcome.2
Interestingly, the MVD measured in our study showed a
statistically significant correlation with the GEP global
‘stromal score’ but not with the individual angiogenesis-
related ‘stromal-2’ signature nor with the CD-31 mRNA
expression levels of each case. The fact that there is no
relationship between the MVD and the ‘stromal-2’ signa-
ture, which includes CD-31 mRNA expression amongst
other genes specifically expressed in the endothelium,
suggests that vascular density is not just a direct surrogate
of high expression levels of angiogenesis-associated genes.
It may reflect an integration of the interplay between
angiogenesis-related genes and genes of the ‘stromal-1’
signature involved in the remodeling of the extracellular
matrix that modulate the process of neoangiogenesis in
tumors. In fact, the new blood vessels formed in the tumor
stroma tend to be highly irregular and tortuous.14,15 The
MVD measured in this study may capture these morpho-
logical features of neoangiogenesis. These findings sup-
port the idea that MVD may be a surrogate biomarker of
the GEP ‘stromal score’ in DLBCL and may help to stratify
these patients according to the biological risk associated
with angiogenesis. 
In our study, the ABC-type DLBCLs showed a higher
MVD than tumors with a GCB profile. The ABC-type
DLBCL arises from a post-germinal center B cell that is
blocked during plasmacytic differentiation, whereas the
GCB-type DLBCL subtype arises from a germinal center B
cell. These two types of DLBCL also differ in their profile
of genetic alterations and dysregulation of molecular path-
ways.16-20 In particular, the ABC type DLBCL shows con-
stitutive activation of NF-kB that may be related to the
presence of mutations in multiple genes regulating this
pathway.21-24 The NF-kB transcription factor has been asso-
ciated with multiple aspects of angiogenesis by regulating
several genes involved in this process such as VEGF, IL-8
and several metalloproteinases, among others.25-27
Therefore, the higher MVD observed in the ABC-type
DLBCL is concordant with the NFkB activation of these
tumors. 
Previous reports have focused on the prognostic value of
angiogenesis in DLBCLs.9,10 In those studies, microvessel
density was evaluated in a semi-quantitative manner and
the immunohistochemical markers differed among stud-
ies.3,9,10 Although different methods were used for evalua-
tion, these papers suggest that both angiogenesis and lym-
phangiogenesis play a role in lymphomas, including
DLBCL.7,8,10,11,28
We approached the evaluation of angiogenesis in
DLBCL using a computerized imaging system. We chose
CD31, the platelet adhesion molecule PECAM1, for the
immunohistochemical evaluation of the microvessels,
since it is one of the genes included in the stromal-2 signa-
ture and because it is expressed both on the vascular and
lymphatic endothelium as opposed to other markers such
as CD34 or FVIII, that are mostly expressed in the vascular
endothelium.29 In our study, we have seen that the total
microvascular area rather than the number of vessels per
area determines the outcome of our patients. This
approach captures the biological significance of angiogen-
esis in DLBCLs and agrees with experimental studies sug-
gesting that the function of the vasculature is more impor-
tant than the vessel count.15,30
T.M. Cardesa-Salzmann et al.
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Table 3. Summary of multivariate analyses in LLMPP and GELCAB
series.
LLMPP GELCAB
(training cohort) (validation set)
N=147 N=118
                                      P value     Relative risk      P value Relative risk
Progression-free survival
MVD (L vs. H)                    0.01                   1.6                    0.05 1.89
IPI (L vs. I vs. H risk)       0.01                   3.1                  <0.001 3.7
Overall survival
MVD (L vs. H)                   0.002                 1.96                  0.016 2.4
IPI (L vs. I vs. H risk)      0.003                  2.7                  <0.001 4.74
MVD: microvessel density; IPI: International Prognostic Index; L: low; I: intermediate; H:
high.
In conclusion, the biological insights gained from this
study provide a new perspective for future clinical trials
incorporating antiangiogenics. On the basis of the results
of both the previous GEP study and the current immuno-
histochemical MVD analysis, it is possible to suggest that
the new antiangiogenic therapies may benefit in particular
a subgroup of patients with aggressive DLBCL character-
ized by a high tumor blood vessel density. 
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